University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Last updated

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) [1] is a National Cancer Institute (NCI)-designated comprehensive cancer center located in Baltimore, Maryland. [2]

Contents

Overview

The UMGCCC is located on the medical campus of the University of Maryland in Baltimore, [3] and is part of the university's medical center and its school of medicine as well. All researchers and physicians at the center are also faculty members of the medical school and other professional schools at the University of Maryland, Baltimore.

The center actively participates in new drug development and conducts pilot studies and Phase I, II and III clinical trials.

In addition to basic and clinical cancer research, cancer center activities include teaching and a strong focus on aggressive treatment for cancer patients in the 40-bed inpatient unit, dedicated Bone Marrow/Stem Cell Transplantation unit, and 25,000-square-foot (2,300 m2) outpatient facility, which opened in 2005.

The center has multidisciplinary clinical programs for all major cancers (breast, brain, cutaneous, head and neck, gastrointestinal, genitourinary, gynecological, hematologic malignancies, and thoracic cancer).

In 2024, UMGCCC was named one of the best hospitals for cancer care by U.S. News and World Report. [4]

History

The University of Maryland's cancer center began as the intramural program of the National Cancer Institute (NCI) of the NIH. In 1965, the NCI created an intramural program in the Division of Cancer Treatment (DCT) located at the U.S. Public Health Service (USPHS) Hospital in Baltimore. Chemotherapy for cancer was beginning to be recognized as an integral part of modern cancer care, and the NCI was at the forefront of new approaches. The impetus for this off-campus intramural program was the need for additional beds for the NCI's in-house Phase I and Phase II studies.

Because the NCI was a Federal organization, officials selected the Federal USPHS Hospital to serve as the source of beds relatively close to the Bethesda campus. The intramural program was formally designated as the Baltimore Cancer Research Center (BCRC) of the NCI. It included 40 beds, an 8-bed intensive care unit (ICU), a radiation oncology unit, and basic science laboratories of pharmacology and biochemistry, each directed by senior NCI personnel. The facility had the advantage of being close to the home campus, and its laboratory base was located in a city with a large patient population for referral for studies. The BCRC was involved in many studies, and the staff were highly productive, publishing multiple peer-reviewed papers in high-quality journals. For example, many patients in the landmark studies of MOPP treatment for Hodgkin's disease were treated at the BCRC.

In 1974 the clinical unit of the BCRC moved to the University of Maryland Medical Center, and in 1976 the BCRC laboratories moved into the University of Maryland School of Medicine. The center remained an intramural NCI program under contractual arrangement between NCI and the University of Maryland at Baltimore. In 1978 its name was changed to the Baltimore Cancer Research Program (BCRP). From its inception, the BCRP was very active in clinical research with protocols developed by BCRP staff and via national groups such as the Cancer and Leukemia Group B (CALGB). The BCRP was also very active in basic and applied laboratory research in pharmacology, enzymology, immunology, and microbiology.

In 1981 the National Cancer Institute divested the Baltimore Cancer Research Program from the federal government, and the University of Maryland School of Medicine and the Medical Center established the University of Maryland Cancer Center.

In 1996, the center's name was changed to the Marlene and Stewart Greenebaum Cancer Center (UMGCC) in recognition of a $10 million gift by its namesake benefactors: Baltimore philanthropists Marlene and Stewart Greenebaum and in 2008, was selected to be a designated cancer center by the NCI becoming 1 of 64 centers throughout the United States to have earned that distinction. [5]

After earning the NCI's highest designation of Comprehensive Cancer Center, the university changed the center's name and since 2016, has been called the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. [2]

Notable Clinical and Research Activities

Related Research Articles

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

NCI-designated Cancer Centers are a group of 72 cancer research institutions in the United States supported by the National Cancer Institute.

<span class="mw-page-title-main">University of Maryland Medical System</span> Not-for-profit corporation based in Baltimore, Maryland

The University of Maryland Medical System (UMMS) is a private, not-for-profit corporation founded in 1984 and based in Baltimore, Maryland. As of 2023, it owns and operates 11 hospitals in Maryland, 4 free-standing emergency rooms and over 150 care locations, including a network of urgent care centers. The System has more than 2,400 licensed beds, 100,000 annual admissions and gross patient revenues of $4.86 billion annually. University of Maryland Medical System medical staff work with University of Maryland School of Medicine specialists to provide primary and specialty care across the state.

<span class="mw-page-title-main">Cancer and Leukemia Group B</span> U.S. research cooperative group

Cancer and Leukemia Group B is a cancer research cooperative group in the United States.

<span class="mw-page-title-main">Gordon McVie</span> British oncologist and cancer researcher (1945–2021)

John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.

The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.

<span class="mw-page-title-main">Yale Cancer Center</span> Hospital in Connecticut, United States

Yale Cancer Center (YCC) was founded in 1974 as a result of an act of Congress in 1971, which declared the nation's "war on cancer". It is one of a network of 56 Comprehensive Cancer Centers designated by the National Cancer Institute (NCI). Currently directed by Dr. Eric Winer, the Cancer Center brings together the resources of the Yale School of Medicine (YSM), Yale New Haven Hospital (YNHH), and the Yale School of Public Health (YSPH).

<span class="mw-page-title-main">University of Maryland Medical Center</span> Hospital in Maryland, United States

The University of Maryland Medical Center (UMMC) is a teaching hospital with 806 beds based in Baltimore, Maryland, that provides the full range of health care to people throughout Maryland and the Mid-Atlantic region. It gets more than 26,000 inpatient admissions and 284,000 outpatient visits each year. UMMC has approximately 9,050 employees at the UMMC Downtown Campus, as well as 1,300 attending physicians and 950 resident physicians across the Downtown and the Midtown campuses. UMMC provides training for about half of Maryland's physicians and other health care professionals. All members of the medical staff are on the faculty of the University of Maryland School of Medicine.

<span class="mw-page-title-main">John E. Niederhuber</span>

John E. Niederhuber was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and co-director, Johns Hopkins Clinical Research Network.

William Douglas Figg is an American scientist (pharmacologist). He is a senior investigator (tenured) at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland. He holds multiple titles within the NCI: Associate Director of the Center for Cancer Research, Co-Director of the Office of Translational Resources, Acting Branch Chief for the Genitourinary Malignancies Branch, Chief of the Clinical Pharmacology Program, and head of the Molecular Pharmacology Section. Figg is also the Co-chief of Basic Research at the Center for Prostate Disease Research within the Walter Reed National Military Medical Center – Murtha Cancer Center in Bethesda, Maryland.

Gibbs Cancer Center & Research Institute is a cancer treatment and research facility in Upstate South Carolina. Gibbs Cancer Center is associated with the NCI Community Cancer Centers Program and the Medical University of South Carolina. Gibbs has several locations across the upstate of South Carolina, including Comprehensive Cancer Centers at both Spartanburg Medical Center and Pelham Medical Center. Additional infusion facilities are located in Gaffney, Union, Mary Black and North Grove.

<span class="mw-page-title-main">Tianjin Medical University Cancer Institute and Hospital</span> Hospital in Tianjin, China

Tianjin Medical University Cancer Institute and Hospital is a cancer research institute based in China.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is an NCI-Designated Comprehensive Cancer Center in Baltimore, MD. It was established in 1973 and received its NCI designation that same year as one of the first designated cancer centers in the country.

<span class="mw-page-title-main">Elizabeth Jaffee</span> American oncologist

Elizabeth M. Jaffee is an American oncologist specializing in pancreatic cancer and immunotherapy.

UCSF Helen Diller Family Comprehensive Cancer Center is an NCI-designated Cancer Center, affiliated with the UCSF School of Medicine and the UCSF Medical Center. It is one of 69 cancer research institutions in the United States supported by the National Cancer Institute, and one of three in Northern California. The HDFCCC integrates basic and clinical science, patient care, and population science to address prevention and early detection of cancer as well as the quality of life following diagnosis and treatment.

Joseph Rocco Bertino was an American researcher in the cancer pharmacology program at Rutgers Cancer Institute of New Jersey and professor of medicine and pharmacology at the Robert Wood Johnson Medical School in New Jersey. His research focused on the treatment of lymphoma.

<span class="mw-page-title-main">Christine Alewine</span> American oncologist and biologist

Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She is an investigator at the National Cancer Institute.

<span class="mw-page-title-main">Deborah E. Citrin</span> American clinician and scientist

Deborah E. Citrin is an American clinician-scientist researching pre-clinical and clinical testing of radiation modifiers and the mechanisms of normal tissue injury from radiation. She is a senior investigator and deputy director of the National Cancer Institute's Center for Cancer Research.

BCRC may refer to:

John Theurer Cancer Center (JTCC) at the Hackensack University Medical Center (HUMC), and part of the Hackensack Meridian Health (HMH), specializes in oncology services and treatments. It is known for being the first site approved to use cell-based gene therapy to treat patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment; it initiated the first CAR T-cell therapy clinical trials and is a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center. Other areas of concentration include bone marrow transplants, stem cell transplantation, lymphoma, leukemia, multiple myeloma, neuro-oncology, cutaneous malignancy, gastrointestinal, geriatric, head and neck, thoracic, urologic, breast, and gynecologic. As of 2023, Andre Goy is chair and Chief Physician Officer.

References

  1. ↑ "University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Care". www.umms.org.
  2. 1 2 "University of Maryland Greenebaum Cancer Center Earns National Cancer Institute's Highest Designation". www.umms.org.
  3. ↑ Baltimore, University of Maryland. "UMB Home". University of Maryland, Baltimore.
  4. ↑ "U.S. New & World Report: University of Maryland Medical Center". U.S. New & World Report. July 16, 2024. Retrieved July 16, 2024.
  5. ↑ "Center joins elite group of cancer research and treatment facilities in U.S."
  6. ↑ "Angela Hartley Brodie, PhD".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.